Oruka Therapeutics, Inc.
ORKAOruka Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel monoclonal antibody therapeutics for chronic inflammatory and immunology indications, with a primary focus on psoriasis and related skin diseases.
Earnings
Next report
Aug 10, 2026 (Tomorrow)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Oruka Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel monoclonal antibody therapeutics for chronic inflammatory and immunology indications, with a primary focus on psoriasis and related skin diseases. The company leverages antibody engineering and half-life extension technologies to optimize validated modes of action, aiming to provide superior efficacy and significantly less frequent dosing compared to current standard-of-care treatments.
A clinical-stage challenger focused on improving the dosing frequency and efficacy of established biologic classes through advanced antibody engineering.
FAQ
- What is Oruka Therapeutics, Inc.'s market cap?
- Oruka Therapeutics, Inc. (ORKA) has a market capitalization of $5.9B and trades on XNAS.
- Who are Oruka Therapeutics, Inc.'s competitors?
- Oruka Therapeutics, Inc.'s key competitors include Eli Lilly, AbbVie, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Oruka Therapeutics, Inc. partner with?
- Oruka Therapeutics, Inc.'s notable partners include Paragon Therapeutics, Inc., WuXi Biologics Ireland Limited, Fairmount Funds Management LLC.
- What subsidiaries does Oruka Therapeutics, Inc. have?
- Oruka Therapeutics, Inc.'s subsidiaries include Oruka Therapeutics Operating Company, LLC.
- Where is Oruka Therapeutics, Inc. headquartered?
- Oruka Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.